Bristol-Myers vet Caroline Loew heads up Glympse Bio; Kaleido nabs GSK's CMO Katharine Knobil
→ Bristol-Myers Squibb vet Caroline Loew has traded an R&D strategy and planning role for the top job at Glympse Bio. After a 20-year career in drug development, with stints at Merck and PhRMA, Loew will now lead the Arch-backed startup in advancing its in vivo disease-monitoring activity sensors.
→ Kaleido Biosciences has scooped Katharine Knobil from GlaxoSmithKline to become its CMO and head up R&D. Founded by Flagship Pioneering in 2015 and boosted by a $101 million mega-round this year, the biotech is developing a pipeline of microbiome-based therapies that Knobil is tasked with steering into Phase II in 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.